Phathom Pharmaceuticals, Inc.

Report azionario NasdaqGS:PHAT

Capitalizzazione di mercato: US$664.8m

Phathom Pharmaceuticals Dividendi e riacquisti

Criteri Dividendo verificati 0/6

Phathom Pharmaceuticals non ha registrato alcun pagamento di dividendi.

Informazioni chiave

n/a

Rendimento del dividendo

-18.9%

Rendimento del riacquisto

Rendimento totale per gli azionisti-18.9%
Rendimento futuro dei dividendi0%
Crescita dei dividendin/a
Prossima data di pagamento dei dividendin/a
Data di stacco del dividendon/a
Dividendo per azionen/a
Rapporto di remunerazionen/a

Aggiornamenti recenti su dividendi e riacquisti

Nessun aggiornamento

Recent updates

Aggiornamento narrativa • Sep 09

PHAT: Label Expansion Plans And 2026 Profitability Path Will Support Bullish Repricing

Analysts have reset the fair value estimate for Phathom Pharmaceuticals to $10, reflecting a lower price target that they link to reduced revenue growth and profit margin expectations, a slightly higher discount rate, and more cautious assumptions around Voquezna uptake in a highly genericized market. Analyst Commentary Recent Street research on Phathom Pharmaceuticals points to a more cautious tone around Voquezna and the company’s execution against its growth plans.
Seeking Alpha • Sep 09

Phathom Pharmaceuticals: Specialist Economics Strengthens The Bull Case

Summary Phathom Pharmaceuticals is executing a specialist-focused strategy, targeting gastroenterologists to drive VOQUEZNA adoption and move toward sustainable profitability. Second-quarter 2026 revenue grew 88% to $74.3M, SG&A fell, and management forecasts 2026 revenue of $310–$325M with an 80% gross margin, signaling operating leverage. PHAT’s commercial runway is supported by $182.5M in cash and improved operating cash flows, but revenue-interest financing remains a material risk. Key value drivers include continued growth in covered prescriptions, disciplined spending, and successful as-needed dosing development, with competition from tegoprazan looming. Read the full article on Seeking Alpha
Aggiornamento narrativa • Aug 15

PHAT: Expanded Reflux Indication Will Support Anticipated 2026 Profitability Timeline

Analysts have trimmed the fair value estimate for Phathom Pharmaceuticals from $23.70 to $21.50 as recent cuts to Street price targets, slightly higher discount assumptions, and more cautious revenue growth and margin forecasts feed into updated models. Analyst Commentary Recent Street research on Phathom Pharmaceuticals points to a more cautious stance on valuation, even as several analysts keep positive ratings on the stock.
Aggiornamento narrativa • Jun 15

PHAT: Research Momentum And 2026 Profitability Outlook Will Support Bullish Repricing

Analysts have raised their price target on Phathom Pharmaceuticals to $13.62, reflecting updated assumptions for the discount rate, revenue growth, profit margin, and future P/E following recent research support. What's in the News Phathom highlighted extensive clinical and scientific research on vonoprazan, the active ingredient in VOQUEZNA, at Digestive Disease Week 2026 in Chicago.
Aggiornamento narrativa • Jun 01

PHAT: Clinical Momentum Will Support Anticipated 2026 Profitability Timeline

Analysts have adjusted their price target on Phathom Pharmaceuticals to $23.70. This reflects updated views on the discount rate, long-term margin potential, and future P/E assumptions following recent research commentary.
Aggiornamento narrativa • May 02

PHAT: Regulatory Exclusivity Outlook Will Support Anticipated 2026 Profitability Timeline

Narrative update on Phathom Pharmaceuticals The updated analyst price target for Phathom Pharmaceuticals has moved to $23.70, with analysts pointing to refreshed models that factor in revised revenue growth and profit margin assumptions, an adjusted future P/E, and recent research highlighting expectations around potential profitability timing, regulatory exclusivity and consumer marketing uncertainty. Analyst Commentary Recent Street research on Phathom Pharmaceuticals highlights a mix of optimism around the path to profitability and caution around long term exclusivity and commercial execution.
Aggiornamento narrativa • Apr 15

PHAT: Regulatory Exclusivity Outlook Supports Path To 2026 Profitability

Phathom Pharmaceuticals' fair value estimate has shifted from $22.90 to $23.70 as analysts factor in higher long term profit margin assumptions, recent price target increases to $25 and $13, and updated views on regulatory exclusivity and potential generic competition after 2032. Analyst Commentary Recent Street research provides a mixed but useful view of how expectations are settling around Phathom Pharmaceuticals' execution and long term earnings power.
Aggiornamento narrativa • Apr 01

PHAT: Profitability In 2026 Will Challenge Post 2032 Generic Overhang

Narrative Update The analyst price target for Phathom Pharmaceuticals is now aligned with a fair value estimate of about $13.62, with analysts pointing to updated models following Q4 results, refined assumptions around revenue growth, profit margins and future P/E, as well as recent target increases to $13 and $25 that reflect views on regulatory exclusivity and the path toward potential profitability in early Q3 2026. Analyst Commentary Recent Street research around Phathom Pharmaceuticals has centered on updated models following Q4 results, with analysts adjusting their targets to reflect revised assumptions on regulatory exclusivity, marketing execution and the timing of potential profitability.
Aggiornamento narrativa • Mar 18

PHAT: Profitability In 2026 Will Test Post 2032 Generic Assumptions

Narrative Update on Phathom Pharmaceuticals Analysts have raised Phathom Pharmaceuticals' price target to a range that now reaches up to $25, up from prior targets as low as $12, citing updated models after the Q4 earnings beat, revised assumptions around regulatory exclusivity and generic entry after 2032, and expectations for the company to work toward profitability in early Q3 2026. Analyst Commentary Analysts reviewing Phathom Pharmaceuticals after its Q4 earnings beat have adjusted their models and price targets, but with differing levels of enthusiasm.
Aggiornamento narrativa • Mar 04

PHAT: Profitability Expected In 2026 Could Reframe Long Term Generic Risk

Narrative Update on Phathom Pharmaceuticals The analyst price target underpinning our fair value view on Phathom Pharmaceuticals has shifted from $12 to $13. This reflects updated models that factor in the recent Q4 earnings beat, revised assumptions on regulatory exclusivity and potential generic entry after 2032, and expectations around the company's path toward potential profitability in early Q3 2026.
Aggiornamento narrativa • Feb 18

PHAT: Follow On Equity Raise Will Support Path To 2026 Profitability

Analysts have kept their $22.90 price target for Phathom Pharmaceuticals broadly unchanged, citing only marginal adjustments to inputs such as the discount rate, revenue growth, profit margin, and future P/E assumptions in their valuation work. What's in the News Phathom Pharmaceuticals completed a follow on equity offering totaling approximately US$130.0 million.
Aggiornamento narrativa • Feb 04

PHAT: Equity Raise And 2026 Profitability Outlook Will Support Further Upside

Analysts have maintained their overall view on Phathom Pharmaceuticals, making only modest adjustments to assumptions such as revenue growth, profit margin, and future P/E. Taken together, these inputs support an unchanged fair value estimate of US$22.90 per share.
Aggiornamento narrativa • Jan 20

PHAT: Equity Raise And 2025 Profitability Outlook Will Support Further Upside

Analysts have modestly adjusted their price assumptions for Phathom Pharmaceuticals, and the implied fair value remains at $22.90. Small changes to revenue growth, profit margin expectations, and future P/E assumptions have effectively offset one another.
Articolo di analisi • Jan 08

Revenues Tell The Story For Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) As Its Stock Soars 27%

Despite an already strong run, Phathom Pharmaceuticals, Inc. ( NASDAQ:PHAT ) shares have been powering on, with a gain...
Aggiornamento narrativa • Jan 06

PHAT: Late-Stage Gastrointestinal Trials And 2025 Guidance Will Drive Upside Momentum

Analysts have maintained their price target for Phathom Pharmaceuticals at US$22.90. This reflects only minor adjustments in key model inputs, including the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any change in their overall view.
Aggiornamento narrativa • Dec 16

PHAT: Late-Stage Gastrointestinal Pipeline Progress Will Drive Upside Momentum

Analysts have slightly trimmed their price target on Phathom Pharmaceuticals from approximately $23.13 to $22.90 per share, reflecting modestly higher long term growth and margin expectations, offset by a lower projected valuation multiple. What's in the News First patient dosed in the Phase 2 pHalcon EoE-201 trial of VOQUEZNA tablets for eosinophilic esophagitis in adults, with topline results expected in 2027 (company announcement) Additional analyses from the pivotal Phase 3 pHalcon NERD-301 trial of VOQUEZNA in Non Erosive Reflux Disease published in the American Journal of Gastroenterology, highlighting benefits for nighttime GERD symptoms (company announcement, medical journal) Full year 2025 revenue guidance updated to a range of 170 million dollars to 175 million dollars, indicating expectations for continued commercial ramp (company guidance) Sanjeev Narula appointed Chief Financial and Business Officer, bringing extensive large cap pharma and transaction experience from prior CFO roles at Intra Cellular Therapies, Viatris, and Pfizer divisions (company announcement) Valuation Changes Fair Value Estimate has edged down slightly from approximately $23.13 to $22.90 per share.
Aggiornamento narrativa • Dec 01

PHAT: Clinical Pipeline Advances And Index Inclusion Will Support Upside Momentum

Analysts have maintained their price target for Phathom Pharmaceuticals at $23.13 per share, citing consistent revenue growth expectations and stable profit margin forecasts as the basis for leaving their projections unchanged. What's in the News First patient dosed in Phase 2 pHalcon-EoE-201 clinical trial of VOQUEZNA tablets for eosinophilic esophagitis in adults, with primary and secondary results expected in 2027 (Key Developments) Updated full-year 2025 revenue guidance to a range of $170 million to $175 million (Key Developments) New data from Phase 3 pHalcon-NERD-301 trial for VOQUEZNA published, showing improvements in nocturnal symptoms for Non-Erosive Reflux Disease and highlighting safety considerations (Key Developments) Appointment of Sanjeev Narula as Chief Financial and Business Officer, bringing extensive financial and strategic experience from leadership roles at Intra-Cellular Therapies, Viatris, and Pfizer (Key Developments) Added to S&P Pharmaceuticals Select Industry Index (Key Developments) Valuation Changes Consensus Analyst Price Target remains steady at $23.13 per share with no change from previous estimates.
Aggiornamento narrativa • Nov 17

PHAT: Early Clinical Trial Progress Will Drive Shares Higher

Analysts have maintained their fair value price target for Phathom Pharmaceuticals at $23.13 per share. They cite only marginal adjustments to growth estimates and risk assumptions.
Aggiornamento narrativa • Nov 01

PHAT: Rising Profit Margins Will Drive Stronger Shareholder Value Ahead

Analysts have raised their price target for Phathom Pharmaceuticals from $21.38 to $23.13. They cite an improved profit margin outlook, despite more conservative revenue growth projections.
Aggiornamento narrativa • Sep 04

Gastroenterology Focus Will Unlock Enduring Market Potential

Analysts reaffirmed their price target for Phathom Pharmaceuticals at $21.38, citing 10-year market exclusivity for Voquezna, diminished generic risk, and robust launch metrics as drivers of renewed confidence and market opportunity. Analyst Commentary FDA granted 10-year market exclusivity for Voquezna tablets under GAIN, extending exclusivity to May 2032 with a likely pediatric extension through late 2032.
Articolo di analisi • Jul 19

Why We're Not Concerned Yet About Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) 27% Share Price Plunge

Phathom Pharmaceuticals, Inc. ( NASDAQ:PHAT ) shares have retraced a considerable 27% in the last month, reversing a...
Articolo di analisi • Jun 02

Investors Still Aren't Entirely Convinced By Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) Revenues Despite 54% Price Jump

Phathom Pharmaceuticals, Inc. ( NASDAQ:PHAT ) shareholders are no doubt pleased to see that the share price has bounced...
User avatar
Nuova narrativa • May 09

Focused VOQUEZNA Marketing And Cost Cuts Will Secure 2032 Exclusivity

Phathom focuses on VOQUEZNA's market potential in GERD treatment to drive substantial revenue while aiming for profitability through strategic cost management.
Articolo di analisi • Apr 18

Why We're Not Concerned Yet About Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) 27% Share Price Plunge

Unfortunately for some shareholders, the Phathom Pharmaceuticals, Inc. ( NASDAQ:PHAT ) share price has dived 27% in the...
Seeking Alpha • Dec 11

Phathom Pharmaceuticals: The Large Drop Is, Well, Unfathomable

Summary Phathom Pharmaceuticals, Inc.'s vonoprazan received multiple approvals, but the stock price showed erratic behavior, spiking post-Q2 earnings and plummeting post-Q3 earnings. Despite significant prescription growth and revenue increases, Q3 showed slower progress, raising concerns about the drug's market uptake and second-line approval status. High SG&A expenses and limited cash runway pose financial risks, alongside unclear reasons for stagnant sales despite label expansions. I exited my PHAT position in August and have no plans to reinvest due to these uncertainties and financial concerns. Read the full article on Seeking Alpha
Seeking Alpha • Sep 03

Following Up On Phathom Pharmaceuticals

Summary Today, we're following up on Phathom Pharmaceuticals to see how the marketing rollout of its flagship product VOQUENZA is proceeding. This drug received FDA clearance late last year and is aiming to displace Proton Pump Inhibitors in its market. Management has succeeded in getting the compound covered in most commercial plans and believes VOQUENZA have at least $3 billion in peak sales potential. However, the company is still seeing a significant quarterly cash burn rate and already has a decent chunk of debt on its balance sheet. Read the full article on Seeking Alpha
Seeking Alpha • Jun 26

Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays

Summary Phathom Pharmaceuticals stock has significantly declined since 2021, despite securing FDA approval for Vonoprazan to treat H. pylori infection and GERD. The company faced delays in launching its products due to the presence of a cancer-causing agent in commercial batches, but eventually received full FDA approval. PHAT aims to target a substantial market opportunity with Vonoprazan, potentially leading to a share price rally and challenging a billion-dollar market cap valuation. The delays in launching Voquenza have been frustrating, but now the company is conducting a full launch and may secure a lucrative label expansion with an approval in non-erosive GERD next month. Read the full article on Seeking Alpha

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di PHAT siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di PHAT siano aumentati.

Rendimento dei dividendi rispetto al mercato

Phathom Pharmaceuticals Rendimento dei dividendi rispetto al mercato
Come si colloca il rendimento da dividendo di PHAT rispetto al mercato?
SegmentoRendimento dei dividendi
Azienda (PHAT)n/a
Fondo del 25% del mercato (US)1.4%
Top 25% del mercato (US)4.1%
Media del settore (Pharmaceuticals)1.9%
Analista previsionale (PHAT) (fino a 3 anni)0%

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di PHAT rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di PHAT rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Distribuzione degli utili agli azionisti

Copertura degli utili: Dati insufficienti per calcolare il payout ratio di PHAT per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché PHAT non ha segnalato alcun pagamento.

Scoprire le società che pagano dividendi forti

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/09/11 07:49
Prezzo dell'azione a fine giornata2026/09/11 00:00
Utili2026/06/30
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Phathom Pharmaceuticals, Inc. è coperta da 16 analisti. 10 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Jenna DavidnerBarclays
null nullBMO Capital Markets Equity Research
Kristen KluskaCantor Fitzgerald & Co.